Criteria for the selection of nuclides for radioimmunotherapy
Description
This report describes many factors that need to be considered if radioimmunotherapy is to become a commonplace reality. For beta-emitting radionuclides, two physical features of importance are half-life and energy, with the latter determining the range. These features must be matched to the pharmacokinetics of the carrier and the distribution of the radionuclide, both macroscopically and microscopically. Alpha-particle emitters could be considered for cells that are readily accessible to the labeled antibody and for populations that uniformly and constantly display the targeted antigen or idiotype, e.g., trafficking cells such as T or B lymphocytes. For cells that concentrate the radioactive label, the use of low-energy electrons should be examined. If the radionuclide is translocated to the nucleus, the Auger effect can be particularly lethal because of the high LET-like biological response. 15 refs., 3 figs., 2 tabs
Availability note (English)
Available from NTIS, PC A02/MF A01; 1 as DE88002584.Files
19058308.pdf
Files
(279.9 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:28cd07abb0a002aa7306a65902849a8f
|
279.9 kB | Preview Download |
Additional details
Publishing Information
- Imprint Pagination
- 9 p.
- Report number
- CONF-8607355--1
Conference
- Title
- potential, problems, and prospects.
- Acronym
- Symposium on radiolabeled monoclonal antibodies for imaging and therapy
- Dates
- 20 Jul - 1 Aug 1986.
- Place
- Pascoli (Italy).
INIS
- Country of Publication
- United States
- Country of Input or Organization
- United States
- INIS RN
- 19058308
- Subject category
- S63: RADIATION, THERMAL, AND OTHER ENVIRONMENTAL POLLUTANT EFFECTS ON LIVING ORGANISMS AND BIOLOGICAL MATERIALS; S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Resource subtype / Literary indicator
- Conference
- Descriptors DEI
- ALPHA PARTICLES; ASTATINE 211; AUGER EFFECT; BETA PARTICLES; BIOLOGICAL EFFECTS; BIOLOGICAL LOCALIZATION; BISMUTH 212; CELL CULTURES; CELL KILLING; DOSE-RESPONSE RELATIONSHIPS; DOSIMETRY; ELECTRON CAPTURE; FEASIBILITY STUDIES; FERMIUM 255; IMMUNOTHERAPY; LET; MONOCLONAL ANTIBODIES; PHOSPHORUS 32; RADIOTHERAPY; RBE; SENSITIVITY
- Descriptors DEC
- ACTINIDE NUCLEI; ALPHA DECAY RADIOISOTOPES; ANTIBODIES; ASTATINE ISOTOPES; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BISMUTH ISOTOPES; CAPTURE; CHARGED PARTICLES; DAYS LIVING RADIOISOTOPES; ELECTRON CAPTURE RADIOISOTOPES; ENERGY TRANSFER; EVEN-ODD NUCLEI; FERMIUM ISOTOPES; HEAVY NUCLEI; HELIUM IONS; HOURS LIVING RADIOISOTOPES; IONIZING RADIATIONS; IONS; ISOTOPES; LIGHT NUCLEI; MEDICINE; MINUTES LIVING RADIOISOTOPES; NUCLEI; ODD-EVEN NUCLEI; ODD-ODD NUCLEI; PHOSPHORUS ISOTOPES; RADIATIONS; RADIOISOTOPES; SPONTANEOUS FISSION RADIOISOTO; THERAPY
Optional Information
- Notes
- Portions of this document are illegible in microfiche products.